Equity · Healthcare
ARQT
NASDAQArcutis Biotherapeutics (ARQT)
The line runs $27.29 on 23 July through $32 on 19 October, on a scale from $22.5 to $32.5. Days the market did not trade hold the previous close, flat.
as of Oct 19, 2026
Arcutis Biotherapeutics (ARQT) insider trades
In the 90 days to 21 Oct 2026, Arcutis Biotherapeutics insiders reported 13 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 3 Nov 2025, show no open-market purchase.
Showing the 12 most recent of 13 open-market trades in this window. The figures above count all of them.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Arcutis Biotherapeutics (ARQT) reported financials
SEC EDGARArcutis Biotherapeutics reported revenue of $372.1M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$16.1M.
Arcutis Biotherapeutics (ARQT) earnings
Arcutis Biotherapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $0.11; no next date is announced in SEC filings yet.
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
Arcutis Biotherapeutics (ARQT) institutional holders (13F)
SEC EDGAR11 of the 45 institutional funds we track reported a Arcutis Biotherapeutics position for the quarter ended 30 Jun 2026 — a combined $209.9M; the latest of those filings landed 02 Sep 2026.
Showing the 10 largest of 11 reported positions. The figures above count all of them.
Arcutis Biotherapeutics (ARQT) fails-to-deliver
SECOn 25 Sep 2026, 2 shares of Arcutis Biotherapeutics failed to deliver (about $53).
Congressional trades in Arcutis Biotherapeutics (ARQT)
House disclosuresThe most recent congressional trade disclosed in Arcutis Biotherapeutics is a sale by Gilbert Ray Cisneros, Jr. (house, CA), dated 11 Dec 2025.
Arcutis Biotherapeutics (ARQT): frequently asked questions
Have Arcutis Biotherapeutics insiders bought or sold shares recently?
In the 90 days to 21 Oct 2026, Arcutis Biotherapeutics insiders reported 13 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 3 Nov 2025, show no open-market purchase. A further 7 filings were grants, awards, gifts or exercises rather than open-market trades.
How many institutions hold Arcutis Biotherapeutics?
11 of the 45 institutional funds we track reported a Arcutis Biotherapeutics position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.
Has Arcutis Biotherapeutics had fails-to-deliver recently?
Yes. The most recent SEC fails-to-deliver record for Arcutis Biotherapeutics is dated 25 Sep 2026, when 2 shares failed to deliver.
When did Arcutis Biotherapeutics last report earnings?
Arcutis Biotherapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $0.11; no next date is announced in SEC filings yet.
What exchange is Arcutis Biotherapeutics listed on?
Arcutis Biotherapeutics trades on NASDAQ under the ticker ARQT.
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
Sources
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
- SEC EDGARSEC EDGAR 13F filings
- SECSEC fails-to-deliver (CNS) data
- House disclosuresU.S. House of Representatives financial disclosures
- SEC EDGARValuation computed from SEC EDGAR filings